Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14851348 | 0.88 | KCNH2 (0.34) | PTPN2PTPN1PTPN6CHRM3L3MBTL1 | |
| SCHEMBL3437746 | 0.72 | — | — | |
| SCHEMBL15945460 | 0.70 | L3MBTL1 (0.45) | PTPN2PTPN1PTPN6CHRM3APP | |
| SCHEMBL19827280 | 0.69 | APP (0.49) | PTPN2PTPN1PTPN6CHRM3APP | |
| SCHEMBL12384895 | 0.68 | RAB9A (0.45) | PTPN1TP53NPC1RAB9AMEN1 | |
| SCHEMBL10923678 | 0.68 | APP (0.44) | PTPN2PTPN1PTPN6CHRM3APP | |
| SCHEMBL19491256 | 0.67 | APP (0.46) | PTPN2PTPN1PTPN6CHRM3APP | |
| SCHEMBL26016337 | 0.67 | APP (0.42) | PTPN2PTPN1PTPN6CHRM3APP | |
| SCHEMBL10202427 | 0.67 | ADRB2 (0.47) | PTPN2PTPN1PTPN6CHRM3APP | |
| SCHEMBL4367676 | 0.66 | APP (0.55) | CHRM3APPTP53TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130089501-A1 | SOLID-PHASE FLUORINATION OF BENZOTHIAZOLES | HAMMERSMITH IMANET LIMITED (GB) | 2013-04-11 | — | — | US | disclosed |
| US-7264792-B2 | Solid phase preparation of 18F-labelled amino acids | GE HEALTHCARE LIMITED (GB) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089501-A1 | SOLID-PHASE FLUORINATION OF BENZOTHIAZOLES | SLC43A1, SLCO2B1, SLCO2A1 | PTPN2 4765/4885PTPN1 4690/4885PTPN6 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.